Compare Humana Inc (HUM) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Phillips 66 — how do they compare? Humana Inc trades at $433.13 (market cap $46.49B), while Phillips 66 trades at $284.13 (market cap $112.36B). The key difference: Phillips 66 is far larger — about 2.4× Humana Inc's market cap, and Phillips 66 pays the higher dividend (1.8%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Phillips 66 for 62 Days on average.
| HUM | PSX | |
|---|---|---|
Market Cap | $46.49B | $112.36B |
Volume | 2,567,704 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $409.85 | $281.60 |
52-Week Low | $163.67 | $126.76 |
Typical Hold Time | 53 Days | 62 Days |
Enterprise Value | $53.84B | $128.83B |
Dividend Yield | 0.91% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
Phillips 66 (PSX) trades at $271.62, up 0.68% with a bullish technical outlook near its 52-week high. The stock shows strong profitability with 24.02% ROE and 4.66% net margin, supported by three consecutive earnings beats. Recent news highlights structural refining advantages and AI implementation for operational efficiency. Current valuation metrics include a P/E of 16.07 and P/S of 0.75, suggesting reasonable pricing relative to peers.
PSX presents a compelling investment case with analyst consensus at Buy (54% rating) and $279 price target, though revenue declines from 2022-2025 pose concerns. Key risks include diesel export policy uncertainty and refining margin volatility. The company's debt reduction progress and projected 2026 earnings recovery to $7.1B support upside potential if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
